This study focuses on patients with myelodysplastic syndromes (MDS), a group of blood disorders where the bone marrow does not produce enough healthy blood cells. The study specifically looks at patients with low-risk MDS who have anemia (low red blood cell counts) but do not need blood transfusions and have not previously received treatment with drugs that stimulate blood cell production.

The medication being tested is called luspatercept (Reblozyl), which is given as an injection under the skin. This treatment aims to improve the body’s ability to produce red blood cells and increase hemoglobin levels in patients with MDS. The medication will be given to patients for up to 24 weeks to see if it can help improve their anemia.

The study will measure how well the treatment works by checking if patients’ hemoglobin levels increase by a certain amount and if this improvement lasts for at least 8 weeks. Patients will receive subcutaneous injections of luspatercept at doses that may be adjusted during the study period. The treatment period may continue for up to 18 months for patients who show improvement in their condition.